BioSpace News Archive

Simulations Plus, Inc. (Nasdaq: SLP) announced today that it will report financial results for the first quarter of fiscal year 2023, the period ended November 30, 2022, after the close of the financial markets on Wednesday, January 4, 2023.

Ikena Oncology, Inc. announced that after a successful 4-year tenure as Chairman of the Board of Directors, Ron Renaud will be stepping down from the role to focus on his new position as Managing Director at Bain Capital Life Sciences.

ContraFect Corporation (Nasdaq: CFRX) today announces the database lock of its Phase 3 DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial) study of exebacase in patients with Staph aureus bacteremia, and a summary of the topline data and the preliminary findings from its own analysis of data from the interim futility analysis (the Futility Dataset).

Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company received a clinical hold notice from the U.S. Food and Drug Administration (FDA) regarding their Investigational New Drug Application (IND) for ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy.

Terns Pharmaceuticals, Inc. announced that it has commenced a proposed underwritten public offering of $75.0 million of shares of its common stock.

Oragenics, Inc., a biotech company dedicated to fighting infectious diseases including COVID-19, announced that on December 16, 2022 the Board of Directors appointed Charles Pope as its Chairman of the Board of Directors succeeding Dr. Frederick W. Telling, who has served as a director since June 2010 and as Chairman since February 2011.

Otonomy, Inc. announced that the company’s board of directors, after considering strategic options, has approved and adopted a Plan of Liquidation and Dissolution that would include the distribution of remaining cash to stockholders following an orderly wind down of the company’s operations, including the proceeds from the sale of any pipeline assets.

Regen BioPharma, Inc. and As 2022 comes to a close, I would like to highlight some our many accomplishments achieved this year and also to respond to the multiple queries regarding future business strategy and planning that we have received.

Gilead Sciences, Inc. and Arcus Biosciences, Inc. announced positive results from the fourth interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer with PD-L1 tumor proportion score ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase mutations.

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Levocarnitine Tablets USP, 330 mg.